SenzaGen AB 2020 AR2
The report highlights SenzaGen AB's performance and strategic progress during the 2020 fiscal year. The company tripled its sales to nearly SEK 8 million and achieved GLP certification for its laboratory, enabling it to meet regulatory requirements for product filings. SenzaGen expanded its product portfolio with the launch of the GARD skin Dose-Response test and strengthened its commitment to sustainability by adopting the UN Global Compact's ten principles. Additionally, the company focused on reducing animal testing through its innovative in vitro technology platform.
Company: SenzaGen AB
Sector: Professional & technical services
Country: Sweden
Year: 2020
Type: AR2
Pages: 30
Back to company
SenzaGen AB
Annual Report
The report highlights SenzaGen AB's performance and strategic progress during the 2020 fiscal year. The company tripled its sales to nearly SEK 8 million and achieved GLP certification for its laboratory, enabling it to meet regulatory requirements for product filings. SenzaGen expanded its product portfolio with the launch of the GARD skin Dose-Response test and strengthened its commitment to sustainability by adopting the UN Global Compact's ten principles. Additionally, the company focused on reducing animal testing through its innovative in vitro technology platform.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees